IP Library Granted Patent US 8,697,940
Granted Patent B2
US 8,697,940 · App. 13/890,519 · Granted Apr 15, 2014

ADAM6 mice

Inventors: Lynn Macdonald (White Plains, NY); Sean Stevens (San Francisco, CA); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,697,940
App. No.
13/890,519
Granted
Apr 15, 2014
Kind
B2
Abstract

Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.

Claims (33)

1. A mouse whose genome comprises

(a) an insertion of one or more human V H , one or more human D H , and one or more human J H gene segments upstream of an endogenous heavy chain constant region gene; and

(b) an insertion of one or more human V L and one or more human J L gene segments upstream of an endogenous light chain constant region gene; and

(c) an ectopic nucleic acid sequence that encodes an Adam6 protein that is functional in the mouse,

so that the mouse is characterized in that:

(i) it is fertile; and

(ii) when it is immunized with an antigen, it generates antibodies comprising:

(A) heavy chain variable domains encoded by the one or more human V H , one or more human D H , and one or more human J H gene segments, linked to heavy chain constant domains encoded by the heavy chain constant region gene; and

(B) light chain variable domains encoded by the one or more human V L and one or more human J L gene segments linked to light chain constant domains encoded by the endogenous light chain constant region gene,

wherein the antibodies specifically bind the antigen.

2. The mouse of claim 1 , wherein the ectopic nucleic acid sequence is present at the endogenous heavy chain locus.

3. The mouse of claim 2 , wherein the ectopic nucleic acid sequence is positioned within a human immunoglobulin heavy chain sequence.

4. The mouse of claim 3 , wherein the ectopic nucleic acid sequence is positioned between two human V H gene segments.

5. The mouse of claim 1 , wherein the ectopic nucleic acid sequence is present at a position other than the endogenous heavy chain locus.

6. The mouse of claim 5 , wherein the ectopic nucleic acid sequence is positioned between a V H and a D H gene segment.

7. The mouse of claim 1 , wherein the insertion comprises at least 18 human V H , at least one and up to 27 human D H , and at least one and up to six human J H gene segments.

8. The mouse of claim 1 , wherein the insertion comprises at least 39 human V H , at least one and up to 27 human D H , and at least one and up to six human J H gene segments.

9. The mouse of claim 1 , wherein the insertion comprises 80 human V H , at least one and up to 27 human D H , and at least one and up to six human J H gene segments.

10. The mouse of claim 1 , wherein the mouse lacks endogenous V H , D H and J H gene segments.

11. The mouse of claim 1 , wherein the one or more human V L and one or more human J L gene segments are Vκ and Jκ gene segments.

12. The mouse of claim 11 , wherein the endogenous light chain constant region is a mouse Cκ region.

13. The mouse of claim 11 , wherein the insertion comprises at least 16 human Vκ and at least one and up to five human Jκ gene segments.

14. The mouse of claim 11 , wherein the insertion comprises at least 30 human Vκ and at least one and up to five human Jκ gene segments.

15. The mouse of claim 11 , wherein the insertion comprises at least 40 human Vκ and at least one and up to five human Jκ gene segments.

16. The mouse of claim 11 , wherein the mouse lacks endogenous Vκ and Jκ gene segments.

17. An isolated mouse cell whose genome comprises:

(a) an insertion of one or more human V H , one or more human D H , and one or more human J H gene segments upstream of an endogenous heavy chain constant region; and

(b) an insertion of one or more human V L and one or more human J L gene segments upstream of an endogenous light chain constant region; and

(c) an ectopic nucleic acid sequence that encodes an Adam6 protein that is functional in the mouse.

18. The isolated cell of claim 17 , wherein the cell is an embryonic stem (ES) cell.

19. A method of making a mouse comprising introducing the ES cell of claim 18 into a host embryo gestating the host embryo in a surrogate mother, and allowing the surrogate mother to give birth to progeny derived in whole or in part from the ES cell.

20. The isolated cell of claim 17 , wherein the cell is a B cell.

21. A hybridoma made from the B cell of claim 20 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2019
From: KAROW, MARGARET
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 049592/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2013
From: MACDONALD, LYNN; STEVENS, SEAN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 030407/0188 →
Continuity (5)
Continuation 13404075 · Feb 24, 2012
Provisional Application 61595200 · Feb 6, 2012
Provisional Application 61446895 · Feb 25, 2011
Provisional Application 61497650 · Jun 16, 2011
Related Publication 20130254911A1 · Sep 26, 2013